A Novel Oncogenic Driver in a Lung Adenocarcinoma Patient Harboring an EGFR-KDD and Response to Afatinib

• Main Authors: Dong Chen, Xing-liang Li, Biao Wu, Xiao-bin Zheng, Wen-xian Wang, Hua-fei Chen, Yi-yu Dong, Chun-wei Xu, Mei-yu Fang
• Format: Article
• Language: English
• Published: Frontiers Media S.A. 2020-06-01
• Series: Frontiers in Oncology
• Subjects: non-small cell lung cancer; epidermal growth factor receptor; kinase domain; next-generation sequencing; afatinib
• Online Access: https://www.frontiersin.org/article/10.3389/fonc.2020.00867/full
• ISSN: 2234-943X

Introduction: Oncogenic mutations in the epidermal growth factor receptor (EGFR) occur frequently in patients with lung cancer. These mutations may serve as critical predictive biomarkers in patients with non-small cell lung cancer (NSCLC). Among them, EGFR exon 18–25 kinase domain duplication (EGFR-KDD) mutations have been identified as a novel EGFR gene subtype in NSCLC.Case Presentation: We reported a rare case of a 59-year-old male diagnosed with adenocarcinoma. A biopsy revealed an EGFR-KDD identified by the next generation sequencing (NGS). Effective treatment outcome has been observed after administration with afatinib.Conclusion: This case highlights that comprehensive NGS technique is valuable in detecting novel genetic mutations in tumors.